Sign Up Today and Learn More About Alumis Stock
Invest in or calculate the value of your shares in Alumis or other pre-IPO companies through EquityZen's platform.
Alumis Stock (ALUM)
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
About Alumis Stock
Founded
2021
Headquarters
San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Alumis Press Mentions
Stay in the know about the latest news on Alumis
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
benzinga • Nov 20, 2024
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
globenewswire • Nov 13, 2024
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga • Nov 01, 2024
Alumis to Participate in Upcoming September Investor Conferences
morningstar • Sep 03, 2024
Alumis Announces Pricing of Initial Public Offering
globenewswire • Jul 04, 2024
Alumis Management
Leadership team at Alumis
Board of Directors
Alan Colowick
Board Member
Michael Rome
Join now and verify your accreditation status to gain access to:
- Alumis current valuation
- Alumis stock price
- Available deals in Alumis and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Alumis Stock
How to invest in Alumis stock?
Accredited investors can buy pre-IPO stock in companies like Alumis through EquityZen funds. These investments are made available by existing Alumis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Alumis stock?
Shareholders can sell their Alumis stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
